

Data Set Name: *accordion_key_v2.sas7bdat*

Num	Variable	Type	Len	Label
1	MaskID	Num	8	ACCORD Participant Identifier
2	female	Num	8	Gender: 0=Male, 1=Female
3	raceclass2	Char	20	Race Class: Non-White, White
4	baseline_age	Num	8	Age (yrs): Randomization
5	arm	Num	8	Randomization Arm: 1-8
6	treatment	Char	50	Treatment Assignment: description
7	trial_elig	Num	8	Participant eligible for BP and Lipid Trials: 0=No, 1=Yes
8	cvd_hx_baseline	Num	8	CVD History at Baseline: 0=No, 1=Yes
9	network	Num	8	Network Identifier: 1-7
10	accordion	Num	8	Monitored in ACCORDION: 0=No, 1=Yes
11	accord_primary	Num	8	accord_primary: 0/1 indicator of complete follow-up for primary outcome in ACCORD
12	accord_vital	Num	8	accord_vital: 0/1 indicator of complete follow-up for vital status in ACCORD
13	accordion_primary	Num	8	accordion_primary: 0/1 indicator of complete follow-up for primary outcome in ACCORDION
14	accordion_vital	Num	8	accordion_vital: 0/1 indicator of complete follow-up for vital status in ACCORDION

Data Set Name: *bloodpressure.sas7bdat*

Num	Variable	Type	Len	Format	Informat	Label
1	MASKID	Num	8			ACCORD Participant Identifier
2	VISIT	Char	10			Visit: BLR=Baseline, EXIT=Trial exit visit, F## where numeric is study months, PT1=First post-trial clinic visit, PT3=Third post-trial clinic visit
3	SBP	Num	8	6.	6.	Systolic BP (mm Hg)
4	DBP	Num	8	6.	6.	Diastolic BP (mm Hg)
5	HR	Num	8	6.	6.	Heart Rate (beats/min)

Data Set Name: concomitantmeds.sas7bdat

Num	Variable	Type	Len	Format	Informat	Label
1	MASKID	Num	8			ACCORD Participant Identifier
2	DAYS_FROM_BASELINE	Num	8			Study Days: number of days following randomization
3	LOOP	Num	8	11.	11.	Loop diuretics
4	THIAZIDE	Num	8	11.	11.	Thiazide diuretics
5	ACEI	Num	8	11.	11.	Ace inhibitors
6	POTASSIUM	Num	8	11.	11.	Potassium supplements
7	A2RB	Num	8	11.	11.	Angiotensin type 2 antagonists (ARB)
8	ALPHA_BLOCKER	Num	8	11.	11.	Peripheral alpha-blockers
9	DHP_CCB	Num	8	11.	11.	Dihydropyridine calcium channel blockers
10	NONDHP_CCB	Num	8	11.	11.	Non-dihydropyridine calcium channel blockers
11	CENTRAL_AGENT	Num	8	11.	11.	Central alpha-adrenergic agonists
12	BETA_BLOCKER	Num	8	11.	11.	Beta-blockers
13	ARB	Num	8	1.	1.	ARB
14	RESERPINE	Num	8	11.	11.	Reserpine
15	KSPARING	Num	8	11.	11.	Ksparing diuretics
16	VASODILATOR	Num	8	11.	11.	Vasodilators
17	OTHER_BP MED	Num	8	6.	6.	Other antihypertensive agents
18	DIGITALIS	Num	8	11.	11.	Digitalis preparations
19	ANTIARRHYTHMIC	Num	8	11.	11.	Anti-arrhythmics
20	NITRATE	Num	8	11.	11.	Nitrates
21	OTHER_CV MED	Num	8	6.	6.	Other cardiovascular drugs
22	SULFONYLUREA	Num	8	11.	11.	Sulfonylureas
23	BIGUANIDE	Num	8	11.	11.	Biguanides
24	TZD	Num	8	11.	11.	Thiazolidinediones
25	AG_INHIBITOR	Num	8	11.	11.	Alpha-glucosidase inhibitors
26	NPHL_INSULIN	Num	8	11.	11.	NPH or L Insulins
27	REG_INSULIN	Num	8	11.	11.	Regular Insulins
28	LA_INSULIN	Num	8	11.	11.	Lispro or Aspart Insulins
29	INCRETIN_AG	Num	8	1.	1.	Incretin Agonists
30	PREMIX_INSULIN	Num	8	11.	11.	Premixed Insulins
31	MEGLITINIDE	Num	8	11.	11.	Meglitinides
32	DPP4_INH	Num	8	1.	1.	DPP-4 Inhibitors
33	OTHER_DIABMED	Num	8	6.	6.	Other Diabetes Treatments
34	BILE_SEQUESTRANT	Num	8	11.	11.	Bile-acid sequestrants
35	STATIN	Num	8	11.	11.	HMG CoA reductatce inhibitors (statins)
36	FIBRATE	Num	8	11.	11.	Fibrates

Num	Variable	Type	Len	Format	Informat	Label
37	OTHER_LIPIDMED	Num	8	11.	11.	Miscellaneous lipid-lowering drugs
38	CHOLEST_ABI	Num	8	6.	6.	Cholesterol absorption inhibitors
39	NIACIN	Num	8	11.	11.	Niacin and nicotinic acid
40	ANTI_COAG	Num	8	11.	11.	Oral antiticoagulants (warfarin, coumadin, anisindione)
41	ANTI_INFLAM	Num	8	11.	11.	Non-steroidal anti-inflammatory agents (excluding aspirin)
42	PLATELET_AGI	Num	8	11.	11.	Inhibitors of platelet aggregations (except aspirin)
43	COX2	Num	8	11.	11.	Cox-2 inhibitors
44	ASPIRIN	Num	8	11.	11.	Aspirin
45	PROGESTIN	Num	8	11.	11.	Progestins
46	ESTROGEN	Num	8	11.	11.	Estrogens (excluding vaginal creams)
47	THYROID	Num	8	11.	11.	Thyroid agents
48	ORAL_ASTHMA	Num	8	11.	11.	Oral asthma drugs (except steroids)
49	INHALED_ASTHMA	Num	8	11.	11.	Inhaled steroids for asthma
50	ORAL_STEROID	Num	8	11.	11.	Oral steroids
51	ANTI_DEPRESS	Num	8	11.	11.	Any antidepressant
52	ANTI_PSYCH	Num	8	6.	6.	Any antipsychotic
53	OSTEOPOROSIS	Num	8	6.	6.	Drugs for osteoporosis
54	FLUID_RETENTION	Num	8	6.	6.	Diuretic for fluid retention
55	MEM_LOSS	Num	8	1.	1.	Any medicine for memory loss
56	OTHER_MED	Num	8	11.	11.	Any other prescribed medication
57	VITAMIN	Num	8	6.	6.	Vitamins and/or nutritional supplements
58	OTC	Num	8	6.	6.	Over the counter medications
59	HERBAL	Num	8	6.	6.	Herbal/alternative medication therapies

Data Set Name: cvdoutcomes.sas7bdat

Num	Variable	Type	Len	Label
1	MASKID	Num	8	ACCORD Participant Identifier
2	CENSOR_PO	Num	8	Primary outcome censoring flag (0=event, 1=censored)
3	FUYRS_PO	Num	8	Primary outcome follow-up time (years)
4	CENSOR_TM	Num	8	Total mortality censoring flag (0=event, 1=censored)
5	FUYRS_TM	Num	8	Total mortality Follow-up time (years)
6	CENSOR_CM	Num	8	CVD mortality censoring flag (0=event, 1=censored)
7	FUYRS_CM	Num	8	CVD mortality Follow-up time (years)
8	CENSOR_NMI	Num	8	Nonfatal MI censoring flag (0=event, 1=censored)
9	FUYRS_NMI	Num	8	Nonfatal MI Follow-up time (years)
10	CENSOR_NST	Num	8	Nonfatal stroke censoring flag (0=event, 1=censored)
11	FUYRS_NST	Num	8	Nonfatal stroke Follow-up time (years)
12	CENSOR_TST	Num	8	Total stroke censoring flag (0=event, 1=censored)
13	FUYRS_TST	Num	8	Total stroke Follow-up time (years)
14	CENSOR_CHF	Num	8	CHF censoring flag (0=event, 1=censored)
15	FUYRS_CHF	Num	8	CHF Follow-up time (years)
16	CENSOR_EX	Num	8	Exp. Macro censoring flag (0=event, 1=censored)
17	FUYRS_EX	Num	8	Exp. Macro Follow-up time (years)
18	CENSOR_MAJ	Num	8	Major CHD censoring flag (0=event, 1=censored)
19	FUYRS_MAJ	Num	8	Major CHD Follow-up time (years)
20	CENSOR_MSD	Num	8	MI, Stroke or Any Death censoring flag (0=event, 1=censored)
21	FUYRS_MSD	Num	8	MI, Stroke or Any Death Follow-up time (years)

Data Set Name: ecg.sas7bdat

Num	Variable	Type	Len	Label
1	MASKID	Num	8	ACCORD Participant Identifier
2	VISIT	Char	15	Visit: BLR=Baseline, EXIT=Trial exit visit, F## where numeric is study months, PT1=First post-trial clinic visit, PT3=Third post-trial clinic visit
3	MC_2	Char	40	MINN Code 2 - QRS Axis Deviation
4	MC_3	Char	40	MINN Code 3 - High Amplitude R Waves
5	MC_7	Char	40	MINN Code 7 - Ventricular Conduction Defect
6	MC_91	Char	40	MINN Code 91 - Low QRS amplitude
7	MC_94	Char	40	MINN Code 94 - QRS transition zone
8	MC_95	Char	40	MINN Code 95 - T wave amplitude \geq 12 mm
9	MCR_81	Char	40	Premature beats by visual flag
10	MCR_83	Char	40	Atrial fibrillation/flutter by visual flag
11	MC_F4	Char	40	MINN Code 4 - ST Junction and Segment Depression Posterior Site
12	MC_F5	Char	40	MINN Code 5 - T-Wave Items Posterior Site
13	MC_F92	Char	40	MINN Code 92 - ST Segment Elevation Posterior Site
14	MC_L4	Char	40	MINN Code 4 - ST Junction and Segment Depression Anterolateral Site
15	MC_L5	Char	40	MINN Code 5 - T-Wave Items Anterolateral Site
16	MC_L92	Char	40	MINN Code 92 - ST Segment Elevation Anterolateral Site
17	MC_V4	Char	40	MINN Code 4 - ST Junction and Segment Depression Anterior Site
18	MC_V5	Char	40	MINN Code 5 - T-Wave Items Anterior Site
19	MC_V92	Char	40	MINN Code 92 - ST Segment Elevation Anterior Site
20	HEART_RT	Num	8	Heart Rate
21	PR_DUR	Num	8	R axis
22	QRS_DUR	Num	8	QRS Duration
23	QT_DUR	Num	8	QT Duration
24	QTC_DUR	Num	8	Bazzett QTc Calculated
25	P_AXIS	Num	8	P axis
26	QRS_AXIS	Num	8	QRS Axis
27	T_AXIS	Num	8	T axis
28	RAMP_AVL	Num	8	Rwave amplitude, Lead aVL
29	SAMP_V3	Num	8	Swave amplitude, Lead v3
30	QTI	Num	8	QT Index
31	JTI	Num	8	JT Index
32	SDNN	Num	8	HRV Standard Deviation of NN intervals
33	RMSD	Num	8	HRV Root Mean Squared Difference
34	CV	Num	8	Cornell Voltage
35	CP	Num	8	Cornell Product
36	MC_1	Char	40	MINN Code 1 - Q and QS Patters

Num	Variable	Type	Len	Label
37	MCR_8X	Char	40	Any other Arrhythmia by visual flag
38	MC_6	Char	40	MINN Code 6 - AV Conduction Defect
39	QUALITY	Char	10	Quality Score

Data Set Name: eye.sas7bdat

Num	Variable	Type	Len	Label
1	MASKID	Num	8	ACCORD Participant Identifier
2	ETDRS0	Num	8	Baseline - Early treatment: Diabetic Retinopathy Photograph Grading scale
3	ETDRS4	Num	8	4 Yrs Early treatment: Diabetic Retinopathy Photograph Grading scale
4	EVENT	Num	8	ACCORD (4 Yrs follow-up): Eye Event (0=no, 1=Yes)
5	ETDRS8	Num	8	8 Yrs - Early treatment: Diabetic Retinopathy Photograph Grading
6	EVENT_8	Num	8	ACCORDION (8 Yrs follow-up): Eye Event (0=No, 1=Yes)

Data Set Name: hba1c.sas7bdat

Num	Variable	Type	Len	Format	Informat	Label
1	MASKID	Num	8			ACCORD Participant Identifier
2	VISIT	Char	10			Visit: BLR=Baseline, EXIT=Trial exit visit, F## where numeric is study months, PT1=First post-trial clinic visit, PT3=Third post-trial clinic visit
3	HBA1C	Num	8	6.2	6.2	Glycated hemoglobin (%)

Data Set Name: hypoglycemiaevents.sas7bdat

Num	Variable	Type	Len	Format	Label
1	MASKID	Num	8		ACCORD Participant Identifier
2	SEVHYPO_TOT	Num	8		Number of hypoglycemic events requiring medical or paramedical attention
3	YRSRISK_TOT	Num	8	4.1	Time at risk (years) for hypoglycemic events

Data Set Name: lipids.sas7bdat

Num	Variable	Type	Len	Format	Informat	Label
1	MASKID	Num	8			ACCORD Participant Identifier
2	VISIT	Char	10			Visit: BLR=Baseline, F## where numeric is study months, EXIT=Trial exit visit, PT1=First post-trial clinic visit, PT3=Third post-trial clinic visit
3	CHOL	Num	8	6.	6.	Total cholesterol (mg/dl)
4	TRIG	Num	8	6.	6.	Triglycerides (mg/dl)
5	VLDL	Num	8	6.	6.	Very low density lipoprotein (mg/dl)
6	LDL	Num	8	6.	6.	Low density lipoprotein (mg/dl)
7	HDL	Num	8	6.	6.	High density lipoprotein (mg/dl)

Data Set Name: mind.sas7bdat

Num	Variable	Type	Len	Format	Informat	Label
1	MASKID	Num	8			ACCORD Participant Identifier
2	VISIT	Char	3			Visit: BLR=Baseline, F## where numeric is study months
3	TOTAL_DSC	Num	8	11.	11.	DSST Total Score
4	TOTAL_MMSE	Num	8	11.	11.	MMSE Total Score
5	STROOP	Num	8			STROOP Interference Score
6	RAVLT	Num	8			RAVLT Score

Data Set Name: mind_mri.sas7bdat

Num	Variable	Type	Len	Label
1	MASKID	Num	8	ACCORD Participant Identifier
2	VISIT	Char	3	Visit: BLR=Baseline, F## where numeric is study months
3	TOTAL_BRAIN_VOLUME_ICV	Num	8	Intracranial Volume (cc, algorithm)
4	BASAL_GANGLIA_NOR	Num	8	Basal Ganglia Normal (cc)
5	BASAL_GANGLIA_ABN	Num	8	Basal Ganglia Abnormal (cc)
6	GRAY_MATTER_NORMAL_SUM	Num	8	Gray Matter, Normal (cc, summed)
7	WHITE_MATTER_NORMAL_SUM	Num	8	White Matter, Normal (cc, summed)
8	GRAY_MATTER_ABNORMAL_SUM	Num	8	Gray Matter, Abnormal (cc, summed)
9	WHITE_MATTER_ABNORMAL_SUM	Num	8	White Matter, Abnormal (cc, summed)
10	BRAIN_VOLUME_NORMAL_SUM	Num	8	Brain Volume, Normal (cc, summed)
11	BRAIN_VOLUME_ABNORMAL_SUM	Num	8	Brain Volume, Abnormal (cc, summed)
12	GRAY_MATTER_TOTAL_SUM	Num	8	Gray Matter, Total (cc, summed)
13	WHITE_MATTER_TOTAL_SUM	Num	8	White Matter, Total (cc, summed)
14	BRAIN_VOLUME_TOTAL_SUM	Num	8	Brain Volume, Total (cc, summed)

Data Set Name: otherlabs.sas7bdat

Num	Variable	Type	Len	Format	Informat	Label
1	MASKID	Num	8			ACCORD Participant Identifier
2	VISIT	Char	10			Visit: BLR=Baseline, EXIT=Trial exit visit, F## where numeric is study months, PT1=First post-trial clinic visit, PT3=Third post-trial clinic visit
3	ALT	Num	8	6.	6.	ALT (mg/dL)
4	SCREAT	Num	8	6.2	6.2	Serum creatinine (mg/dL)
5	GFR	Num	8	15.2	15.2	eGFR from 4 variable MDRD equation (ml/min/1.73 m2)
6	UALB	Num	8	7.2	7.2	Urinary albumin (mg/dL)
7	UCREAT	Num	8	6.1	6.1	Urinary creatinine (mg/dL)
8	UACR	Num	8			Urinary albumin to creatinine ratio (mg/g)

Data Set Name: *healthutilitiesindex.sas7bdat*

Num	Variable	Type	Len	Label
1	MASKID	Num	8	ACCORD Participant Identifier
2	DAYS_FROM_BASELINE	Num	8	Study Days: number of days following randomization
3	HUI3SCOR	Num	8	Health Utilities Index Mark3 (HUI3) - Aggregate score of vision, hearing, speech, ambulation, dexterity, emotion, cognition and pain
4	HUI2SCOR	Num	8	Health Utilities Index Mark2 (HUI2) - Aggregate score of sensation, mobility, cognition, self-care, emotion, pain and fertility

Data Set Name: hrql.sas7bdat

Num	Variable	Type	Len	Label
1	MASKID	Num	8	ACCORD Participant Identifier
2	DAYS_FROM_BASELINE	Num	8	Study Days: number of days following randomization
3	TS09	Num	8	HRQL: Q.1 Little interest in things
4	TS10	Num	8	HRQL: Q.2 Feeling down
5	TS11	Num	8	HRQL: Q.3 Trouble sleeping
6	TS12	Num	8	HRQL: Q.4 Feeling tired
7	TS13	Num	8	HRQL: Q.5 Poor appetite
8	TS14	Num	8	HRQL: Q.6 Feeling bad about self
9	TS15	Num	8	HRQL: Q.7 Trouble concentrating
10	TS16	Num	8	HRQL: Q.8 Move slowly or restless
11	TS17	Num	8	HRQL: Q.9 Thoughts about death
12	TREATTIMES	Num	8	HRQL: Q.10 Visit physician past 30 days (N)
13	PHQ9	Num	8	PHQ9 Total Score

Data Set Name: *inclinicfollowup.sas7bdat*

Num	Variable	Type	Len	Format	Informat	Label
1	MASKID	Num	8			ACCORD Participant Identifier
2	DAYS_FROM_BASELINE	Num	8			Study Days: number of days following randomization
3	CONTACT_TYPE	Char	25			In-Clinic Follow-Up: Q1. Contact Type
4	HOSPITAL	Num	8	11.	11.	In-Clinic Follow-Up: Q.4a Admitted to the hospital
5	ADMITTED	Char	10			In-Clinic Follow-Up: Q.4a Hospitalized, times admitted
6	DIALYSIS	Num	8	11.	11.	In-Clinic Follow-Up: Q.5 Dialysis
7	SMOKED	Num	8	11.	11.	In-Clinic Follow-Up: Q.7 Smoked in last 30 days
8	HEALTH	Num	8	11.	11.	In-Clinic Follow-Up: Q.8 Health rating
9	RATEHEALTH	Num	8	11.	11.	In-Clinic Follow-Up: Q.9 Health compared to last year
10	LIVING_SITUATION	Char	75			In-Clinic Follow-Up: Q.10 Living situation
11	HELPDRPLAN	Num	8	4.	4.	In-Clinic Follow-Up: Q.11 Help follow Dr plan
12	HELPMED	Num	8	4.	4.	In-Clinic Follow-Up: Q.12 Help remember medicine
13	HELPCHECK	Num	8	4.	4.	In-Clinic Follow-Up: Q.13 Help remember check blood sugar levels
14	INS_COVER	Num	8			In-Clinic Follow-Up: Q.14 Insurance Coverage, combined (1=yes)
15	DK_UNINS	Num	8			In-Clinic Follow-Up: Q.14 Unknown insurance/uninsured, combined (1=yes)
16	DRUG_BENEFIT	Char	20			In-Clinic Follow-Up: Q.15 Drug benefits
17	ANOTTRIAL	Num	8	6.	6.	In-Clinic Follow-Up: Q.18a Participate in another trial
18	ANOTTRIALDRUGS	Num	8	6.	6.	In-Clinic Follow-Up: Q.18b Drugs with other trial
19	WT_KG	Num	8			In-Clinic Follow-Up: Q.19 Weight, converted as needed (kg)
20	HT_CM	Num	8			In-Clinic Follow-Up: Q.20 Height, converted as needed (cm)
21	WAIST_CM	Num	8			In-Clinic Follow-Up: Q.21 Waist circumference, converted as needed (cm)
22	SBP	Num	8			In-Clinic Follow-Up: Q.22 Systolic BP (average of 3) [mm Hg]
23	DBP	Num	8			In-Clinic Follow-Up: Q.23 Diastolic BP (average of 3) [mm Hg]
24	HR	Num	8			In-Clinic Follow-Up: Q.24 Heart rate (average of 3) [bpm]
25	EYESURG	Num	8	6.	6.	In-Clinic Follow-Up: Q.25 Eye surgery
26	RE_CAT_YAG	Num	8			In-Clinic Follow-Up: Q.25 RE Cataract/Yag Laser, combined
27	RE_RET_VIT	Num	8			In-Clinic Follow-Up: Q.25 RE Retinal Laser/Vitrectomy, combined
28	RE_OTH	Num	8	1.	1.	In-Clinic Follow-Up: Q.25 RE Other
29	LE_CAT_YAG	Num	8			In-Clinic Follow-Up: Q.25 LE Cataract/Yag Laser, combined
30	LE_RET_VIT	Num	8			In-Clinic Follow-Up: Q.25 LE Retinal Laser/Vitrectomy, combined
31	LE_OTH	Num	8	1.	1.	In-Clinic Follow-Up: Q.25 LE Other
32	RETPATHY	Num	8	6.	6.	In-Clinic Follow-Up: Q.26a Retinopathy
33	LRTPATHY	Num	8	1.	1.	In-Clinic Follow-Up: Q.26a Retinopathy, LE

Num	Variable	Type	Len	Format	Informat	Label
34	RRTPATHY	Num	8	1.	1.	In-Clinic Follow-Up: Q.26a Retinopathy, RE
35	VISLOSS	Num	8	6.	6.	In-Clinic Follow-Up: Q.26b Vision loss
36	LE_VLOSS	Num	8	1.	1.	In-Clinic Follow-Up: Q.26b Vision loss, LE
37	RE_VLOSS	Num	8	1.	1.	In-Clinic Follow-Up: Q.26b Vision loss, RE
38	BLINDNESS	Num	8	6.	6.	In-Clinic Follow-Up: Q.26c Blindness
39	BLINDLT	Num	8	1.	1.	In-Clinic Follow-Up: Q.26c Blindness, LE
40	BLINDRT	Num	8	1.	1.	In-Clinic Follow-Up: Q.26c Blindness, RE
41	INTRAOCULARRE	Num	8	11.	11.	In-Clinic Follow-Up: Q.27A Injections in RE
42	INTRAOCULARLE	Num	8	11.	11.	In-Clinic Follow-Up: Q.27A Injections in LE
43	FAMPHIS	Num	8			In-Clinic Follow-Up: Q.28 Lower extremity amputation, R/L combined
44	F_APPEARANCE	Char	30			In-Clinic Follow-Up: Q.28a Appearance and/or Ulceration, R/L combined
45	FDEFORM	Num	8			In-Clinic Follow-Up: Q.28a Appearance: Deformities, R/L combined
46	FDRYSKI	Num	8			In-Clinic Follow-Up: Q.28a Appearance: Dry Skin, R/L combined
47	FOTHER	Num	8			In-Clinic Follow-Up: Q.28a Appearance: Other, R/L combined
48	FANKLE	Num	8			In-Clinic Follow-Up: Q.28c Ankle Reflexes, R/L combined
49	FVIBRAT	Num	8			In-Clinic Follow-Up: Q.28d Vibration, R/L combined
50	FFILAM	Num	8			In-Clinic Follow-Up: Q.28e 10gm Filament, R/L combined
51	MNSISCOR	Num	8			In-Clinic Follow-Up: (Q.28) Michigan Neuropathy Screening Instrument, R/L combined
52	FEELING	Num	8			In-Clinic Follow-Up: Feeling Thermometer

Data Set Name: visualacuity.sas7bdat

Num	Variable	Type	Len	Format	Informat	Label
1	MASKID	Num	8			ACCORD Participant Identifier
2	DAYS_FROM_BASELINE	Num	8			Study Days: number of days following randomization
3	SCRRIGHT	Num	8	6.	6.	VISUAL ACUITY SCORE - RIGHT EYE (SUM OF A,B, AND C)
4	SCRLEFT	Num	8	6.	6.	VISUAL ACUITY SCORE - LEFT EYE (SUM OF A,B, AND C)